1-9 of 9
Tong Shen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A48: Ube2v1 promotes EMT and metastasis by suppression of autophagy

Tong Shen, Lingdong Cai, Yuhong Liu, Jianming Li
Journal: Cancer Research
Cancer Res (2018) 78 (10_Supplement): A48.
https://doi.org/10.1158/1538-7445.MOUSEMODELS17-A48
Published: 14 May 2018
View article titled, Abstract A48: Ube2v1 promotes EMT and metastasis by suppression of autophagy
Journal Articles

Abstract 855: Ube2v1 promotes epithelial mesenchymal transition and metastasis in colorectal cancer by epigenetically transcriptional suppression of autophagy

Tong Shen, Dong Ling Cai, Hong Yu Liu, Juan Wen Gan, Ming Li, Ru Jing Wang, Da Peng Guo, Qun Zhou, Xing Xing Lu, Shi Li, Na Li Sun, Ming Jian Li
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 855.
https://doi.org/10.1158/1538-7445.AM2017-855
Published: 01 July 2017
View article titled, Abstract 855: Ube2v1 promotes epithelial mesenchymal transition and metastasis in colorectal cancer by epigenetically transcriptional suppression of autophagy
Journal Articles

Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis

Cheng Xing, Xing-Xing Lu, Peng-Da Guo, Tong Shen, Shen Zhang, Xiao-Shun He, Wen-Juan Gan, Xiu-Ming Li, Jing-Ru Wang, Yuan-Yuan Zhao, Hua Wu, Jian-Ming Li
Journal: Cancer Research
Cancer Res (2016) 76 (1): 83–95.
https://doi.org/10.1158/0008-5472.CAN-14-3595
Published: 03 January 2016
View article titled, Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis
Open the PDF for Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis in another window
Includes: Supplementary data
Journal Articles

Abstract 1519: Tyrosine kinase inhibitors are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance

Kamlesh Sodani, Ye-Hong Kuang, Tong Shen, Saurabh Vispute, Amit K. Tiwari, Yu Lei, Jeferson Lee, Xiang Chen, Charles R. Ashby, Zhe-Sheng Chen
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1519.
https://doi.org/10.1158/1538-7445.AM10-1519
Published: 15 April 2010
View article titled, Abstract 1519: Tyrosine kinase inhibitors are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
Journal Articles

Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B

Elizabeth Hopper-Borge, Xiu Xu, Tong Shen, Zhi Shi, Zhe-Sheng Chen, Gary D. Kruh
Journal: Cancer Research
Cancer Res (2009) 69 (1): 178–184.
https://doi.org/10.1158/0008-5472.CAN-08-1420
Published: 31 December 2008
View article titled, Human Multidrug Resistance Protein 7 (<em>ABCC10</em>) Is a Resistance Factor for Nucleoside Analogues and Epothilone B
Open the PDF for Human Multidrug Resistance Protein 7 (<em>ABCC10</em>) Is a Resistance Factor for Nucleoside Analogues and Epothilone B in another window
Includes: Supplementary data
Journal Articles

Computer-based clinical development: improving efficacy of intravesical chemotherapy of bladder cancer

Jessie Au, Zancong Shen, Tong Shen, Robert Badalament, Donn Young, Pieter Venema, David Pollifrone, Jeffrey Harbrecht, Joseph Chin, Seth Lerner, Brian Miles, Guillaume Wientjes
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4479.
Published: 01 May 2008
View article titled, Computer-based clinical development: improving efficacy of intravesical chemotherapy of bladder cancer
Journal Articles

Reversal of ABCB1- and ABCG2-mediated MDR by erlotinib (tarceva, OSI-774)

Zhi Shi, Xing-Xiang Peng, In-Wha Kim, Suneet Shukla, Qiu-Sheng Si, Robert Robey, Susan Bates, Si-Rong Wang, Christine Chim, Tong Shen, Amit Tiwari, Charles Ashby, Liwu Fu, Suresh Ambudkar, Zhe-Sheng Chen
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 3247.
Published: 01 May 2008
View article titled, Reversal of ABCB1- and ABCG2-mediated MDR by erlotinib (tarceva, OSI-774)
Journal Articles

Nontoxic doses of suramin enhances chemotherapy in pancreatic xenograft tumors

Jing Li, Tong Shen, Jie Wang, Jessie Au, M. Guillaume Wientjes
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4777.
Published: 01 May 2008
View article titled, Nontoxic doses of suramin enhances chemotherapy in pancreatic xenograft tumors
Journal Articles

Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance

Zhi Shi, Xing-Xiang Peng, In-Wha Kim, Suneet Shukla, Qiu-Sheng Si, Robert W. Robey, Susan E. Bates, Tong Shen, Charles R. Ashby, Jr., Li-Wu Fu, Suresh V. Ambudkar, Zhe-Sheng Chen
Journal: Cancer Research
Cancer Res (2007) 67 (22): 11012–11020.
https://doi.org/10.1158/0008-5472.CAN-07-2686
Published: 15 November 2007
View article titled, Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance
Open the PDF for Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance in another window